MAGEA3 and melanoma: BNT111 is a liposomal RNA vaccine encoding four TAAs, MAGE-A3, NY-ESO-1, PTEN, and tyrosinase, and its safety and effectiveness were evaluated in 2015 after intravenous administration in a phase I trial (Lipo-MERIT, NCT02410733).153 This study recruited 89 patients, with 42 suffering from measurable stage III/IV melanoma.